Brief: Avenue Therapeutics - On May 24, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
25/05/2022 22:21
May 25 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS - ON MAY 24, CO RECEIVED NOTICE OF
DELISTING
OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ - FILING
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary